Arun Swarup Menawat
Arun Swarup Menawat's purchase track record
Arun Swarup Menawat has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/15/2025 | PROF | $100K | +22.3% | +40.2% | +13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Profound Medical Featured in AI Healthcare Stock List. Profound Medical Corp. was included in a recent list of three Canadian AI healthcare stocks with market caps up to $296 million. This mention highlights the company's position within the emerging AI health sector. The stock is currently trading near its 52-week low, reflecting a significant drop from its recent high.
Transaction History
| STXS | ▲ Buy | Grant | 43,103 | $0 | 7/1/2026 | View on chart |
| STXS | ▲ Buy | Grant | 46,948 | $0 | 1/2/2026 | View on chart |
| STXS | ▲ Buy | Grant | 43,668 | $0 | 7/1/2025 | View on chart |
| PROF | ▲ Buy | Open Market | 12,027 | $57K | 5/16/2025 | View on chart |
| PROF | ▲ Buy | Open Market | 10,003 | $43K | 5/15/2025 | View on chart |
| STXS | ▲ Buy | Grant | 56,497 | $0 | 1/2/2025 | View on chart |
| STXS | ▲ Buy | Grant | 53,475 | $0 | 7/1/2024 | View on chart |
| STXS | ▲ Buy | Grant | 64,935 | $0 | 1/2/2024 | View on chart |
| STXS | ▲ Buy | Grant | 47,619 | $0 | 7/3/2023 | View on chart |
| STXS | ▲ Buy | Grant | 54,054 | $0 | 1/3/2023 | View on chart |
| STXS | ▲ Buy | Grant | 15,527 | $0 | 7/1/2022 | View on chart |
| STXS | ▲ Buy | Grant | 10,449 | $0 | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
No recent news for STXS
There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.
No recent news for STXS. There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.